0
Original Research: INFECTIONS |

Recombinant Human Deoxyribonuclease in Infants With Respiratory Syncytial Virus Bronchiolitis*

Ruben Boogaard, MD; Anthon R. Hulsmann, MD, PhD; Leoniek van Veen, MD; Anja A. P. H. Vaessen-Verberne, MD, PhD; Yen Ni Yap, MD; Arwen J. Sprij, MD; Govert Brinkhorst, MD; Barbara Sibbles, MD; Tom Hendriks, MD; Sander W. W. Feith, MD; Carsten R. Lincke, MD, PhD; Annelies E. Brandsma, MD, PhD; Paul L. P. Brand, MD, PhD; Wim C. J. Hop, PhD; Matthijs de Hoog, MD, PhD; Peter J. F. M. Merkus, MD, PhD
Author and Funding Information

*From the Department of Pediatric Pulmonology (Drs. Boogaard and Merkus), Erasmus MC-Sophia Children’s Hospital, Rotterdam; Department of Pediatrics (Drs. Hulsmann and Vaessen-Verberne), Amphia Hospital, Breda; Reinier de Graaf Gasthuis (Dr. van Veen), Delft; Albert Schweitzer Hospital (Dr. Yap), Dordrecht; HagaTeaching Hospital/Juliana Children’s Hospital (Dr. Sprij), the Hague; Medisch Centrum Alkmaar (Dr. Brinkhorst), Alkmaar; Erasmus MC-Sophia Children’s Hospital (Drs. Sibbles and de Hoog), Rotterdam; Catharina Hospital (Dr. Hendricks), Eindhoven; Sint Franciscus Gasthuis (Dr. Feith), Rotterdam; Medisch Centrum Rijnmond Zuid (Drs. Lincke and Brandsma), Rotterdam; Isala Klinieken (Dr. Brand), Zwolle; and De-partment of Epidemiology and Biostatistics (Dr. Hop), Erasmus MC, Rotterdam, the Netherlands.

Correspondence to: Ruben Boogaard, MD, Room Sb-2666, Department of Pediatric Pulmonology, Erasmus MC-Sophia Children’s Hospital, Rotterdam, PO Box 2060; 3000 CB Rotterdam, the Netherlands; e-mail: r.boogaard@erasmusmc.nl



Chest. 2007;131(3):788-795. doi:10.1378/chest.06-2282
Text Size: A A A
Published online

Background: Treatment of hospitalized infants with respiratory syncytial virus (RSV) bronchiolitis is mainly supportive. Bronchodilators and systemic steroids are often used but do not reduce the length of hospital stay. Because hypoxia and airways obstruction develop secondary to viscous mucus in infants with RSV bronchiolitis, and because free DNA is present in RSV mucus, we tested the efficacy of the mucolytic drug recombinant human deoxyribonuclease (rhDNase).

Methods: In a multicenter, randomized, double-blind, controlled clinical trial, 225 oxygen-dependent infants admitted to the hospital for RSV bronchiolitis were randomly assigned to receive 2.5 mg bid of nebulized rhDNase or placebo until discharge. The primary end point was length of hospital stay. Secondary end points were duration of supplemental oxygen, improvement in symptom score, and number of intensive care admissions.

Results: There were no significant differences between the groups with regard to the length of hospital stay (p = 0.19) or the duration of supplemental oxygen (p = 0.07). The ratio (rhDNase/placebo) of geometric means of length of stay was 1.12 (95% confidence interval, 0.96 to 1.33); for the duration of supplemental oxygen, the ratio was 1.28 (95% confidence interval, 0.97 to 1.68). There were no significant differences in the rate of improvement of the symptom score or in the number of intensive care admissions.

Conclusions: Administration of rhDNase did not reduce the length of hospital stay or the duration of supplemental oxygen in oxygen-dependent infants with RSV bronchiolitis.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543